AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31178170 — intervention group
Group type: COMPARATOR
Intervention: Non-stented group
Number of subjects: 92
Study 30103785 — intervention group
Group type: EXPERIMENTAL
Intervention: Balancing ACT groups (ACT/PE) plus routine care
Number of subjects: 0
Study 30103785 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 0
Study 26485539 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral access
Number of subjects: 1399
Study 26485539 — intervention group
Group type: COMPARATOR
Intervention: Non-femoral access
Number of subjects: 1399
Study 26485539 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.5 Fr catheters
Number of subjects: 1399
Study 24170763 — intervention group
Group type: EXPERIMENTAL
Intervention: Premixed insulin lispro (insulin lispro mix 25 and/or insulin lispro mix 50)
Number of subjects: 344
Study 24170763 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin glargine plus up to three injections of insulin lispro
Number of subjects: 344
Study 24170763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 344
Study 22455415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5145
Study 22455415 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support-and-education program (Control)
Number of subjects: 5145
Study 21050542 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CAD) system for quantitative lung fibrosis score
Number of subjects: 129
Study 18244892 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention program for weight loss maintenance with features including social support, self-monitoring, written guidelines, and automated reminders.
Number of subjects: 348
Study 18244892 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated email and telephone prompts to encourage website log-ins.
Number of subjects: 348
Study 15986739 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral, sub‐threshold extradural motor cortex stimulation (2 8 Volt, 100‐400 microsec., 20‐120 Hz)
Number of subjects: 16
Study 12913774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg/day in four doses for 48 h)
Number of subjects: 22
Study 12913774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12913774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 22
Study 10347623 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 0
Study 10347623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8536777 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA 150 mg single-dose intramuscular injection
Number of subjects: 80
Study 8536777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1780418 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg)
Number of subjects: 10
Study 1780418 — intervention group
Group type: COMPARATOR
Intervention: 2DG (50 mg/kg)
Number of subjects: 10
Study 6117347 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptics
Number of subjects: 30
Study 6117347 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 30
Study 31287255 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual PCNL (Group A)
Number of subjects: 124
Study 31287255 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCNL (Group B)
Number of subjects: 124
Study 29247519 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 287
Study 24149401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) - 1 g starting 2 hours before surgery, 3 g daily in divided doses (1 g every 8 hours) for 5 days
Number of subjects: 75
Study 24149401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone - single dose of 1 mg/kg at the beginning of surgery
Number of subjects: 75
Study 24149401 — intervention group
Group type: COMPARATOR
Intervention: Control group - no treatment
Number of subjects: 75
Study 24343761 — intervention group
Group type: EXPERIMENTAL
Intervention: E2212 (10-250 mg, single ascending oral doses)
Number of subjects: 0
Study 24343761 — intervention group
Group type: EXPERIMENTAL
Intervention: E2212 (250 mg cohort)
Number of subjects: 0
Study 24343761 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 22931738 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilaser (attachable, adjustable laser)
Number of subjects: 6
Study 22931738 — intervention group
Group type: COMPARATOR
Intervention: No device (control)
Number of subjects: 6
Study 19237833 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 0
Study 19237833 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2) receptor antagonists (H(2)RA)
Number of subjects: 0
Study 19237833 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 0
Study 19237833 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including PPI, H(2)RA, and control)
Number of subjects: 0
Study 17437156 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous bilayer mesh device
Number of subjects: 84
Study 17437156 — intervention group
Group type: COMPARATOR
Intervention: Conventional Prolene hernia system (PHS)
Number of subjects: 84
Study 15203796 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (antidepressant medication) plus standard care (brief counseling and nicotine replacement therapy)
Number of subjects: 134
Study 15203796 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard care (brief counseling and nicotine replacement therapy)
Number of subjects: 134
Study 15203796 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 134
Study 11740317 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV (live attenuated influenza vaccine)
Number of subjects: 49
Study 11740317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 9512235 — intervention group
Group type: EXPERIMENTAL
Intervention: One-embryo transfer
Number of subjects: 0
Study 9512235 — intervention group
Group type: COMPARATOR
Intervention: Two-embryo transfer
Number of subjects: 0
Study 8040679 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) treatment (900 to 3,700 mg/m2 intravenously over 24 hours)
Number of subjects: 134
Study 8040679 — intervention group
Group type: EXPERIMENTAL
Intervention: More aggressive hydration and alkalinization regimen for subsequent courses
Number of subjects: 134
Study 2923290 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal injection of preservative-free morphine sulfate (0.075 mg/kg) in preservative-free normal saline (5-10 ml)
Number of subjects: 32
Study 2923290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study 4914612 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin 100mg daily for six weeks
Number of subjects: 41
Study 4914612 — intervention group
Group type: COMPARATOR
Intervention: Inert capsules for six weeks
Number of subjects: 41
Study 31175958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 720
Study 31175958 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 720
Study 29550173 — intervention group
Group type: EXPERIMENTAL
Intervention: Salad bars installed in schools
Number of subjects: 1193
Study 28662983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stromal cells (AT-MSCs) at a dosage of 1×10^6/kg (group A, n=9) or 3×10^6/kg (group B, n=5) with cyclosporine and prednisone as first-line therapy
Number of subjects: 14
Study 25927404 — intervention group
Group type: EXPERIMENTAL
Intervention: eCO measurement
Number of subjects: 410
Study 25927404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no eCO measurement)
Number of subjects: 410
Study 25927404 — intervention group
Group type: EXPERIMENTAL
Intervention: eCO measurement in smokers (current and former)
Number of subjects: 410
Study 25927404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no eCO measurement) in smokers
Number of subjects: 410
Study 23261916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy group
Number of subjects: 239
Study 23261916 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention group
Number of subjects: 239
Study 23261916 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239
Study 23261916 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 239
Study 21489882 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision of HIV-infected men (intervention group)
Number of subjects: 474
Study 21489882 — intervention group
Group type: COMPARATOR
Intervention: Circumcision of HIV-infected men (control group)
Number of subjects: 474
Study 18266544 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT)
Number of subjects: 86
Study 15906909 — intervention group
Group type: COMPARATOR
Intervention: Standard PN (A)
Number of subjects: 105
Study 15906909 — intervention group
Group type: EXPERIMENTAL
Intervention: PN + glutamine (B)
Number of subjects: 105
Study 15906909 — intervention group
Group type: EXPERIMENTAL
Intervention: PN + omega-3-FA (C)
Number of subjects: 105
Study 12765295 — intervention group
Group type: COMPARATOR
Intervention: Factor VII genotype (R353Q)
Number of subjects: 374
Study 12765295 — intervention group
Group type: COMPARATOR
Intervention: HVR4 polymorphism
Number of subjects: 374
Study 12765295 — intervention group
Group type: COMPARATOR
Intervention: Factor II (G20210A) mutation
Number of subjects: 374
Study 12765295 — intervention group
Group type: COMPARATOR
Intervention: Factor V (G1691A) mutation
Number of subjects: 374
Study 10475716 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5 mg, p.o.)
Number of subjects: 20
Study 10475716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (2 mg, p.o.)
Number of subjects: 20
Study 10475716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (25 mg, p.o.)
Number of subjects: 20
Study 10475716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10475716 — intervention group
Group type: COMPARATOR
Intervention: Control group (received nothing)
Number of subjects: 20
Study 8703521 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 12
Study 1387866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 289
Study 1387866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B hyperimmune globulin (HBIG)
Number of subjects: 289
Study 1387866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine plus HBIG
Number of subjects: 289
Study 1387866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 6149939 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol 10 mg
Number of subjects: 8
Study 6149939 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol 20 mg
Number of subjects: 8
Study 6149939 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg
Number of subjects: 8
Study 6149939 — intervention group
Group type: COMPARATOR
Intervention: terbutaline
Number of subjects: 8
Study 6149939 — intervention group
Group type: COMPARATOR
Intervention: terbutaline up to 3.5 mg
Number of subjects: 8
Study 31639160 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted class
Number of subjects: 87
Study 30424482 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract (NZBC) - 600 mg total (two capsules of 300 mg each containing 35% blackcurrant extract)
Number of subjects: 17
Study 30424482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 17
Study 27374222 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic canola/DHA oil blend (CanolaDHA)
Number of subjects: 84
Study 27374222 — intervention group
Group type: COMPARATOR
Intervention: Conventional canola oil (Canola)
Number of subjects: 84
Study 27374222 — intervention group
Group type: COMPARATOR
Intervention: Corn/safflower oil blend (CornSaff)
Number of subjects: 84
Study 27374222 — intervention group
Group type: COMPARATOR
Intervention: Flax/safflower oil blend (FlaxSaff)
Number of subjects: 84
Study 27374222 — intervention group
Group type: COMPARATOR
Intervention: High oleic canola oil (CanolaOleic)
Number of subjects: 84
Study 25233157 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision surgery for tibial nonunion
Number of subjects: 37
Study 25233157 — intervention group
Group type: COMPARATOR
Intervention: Reamed nail treatment
Number of subjects: 37
Study 25233157 — intervention group
Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 37
Study 25233157 — intervention group
Group type: COMPARATOR
Intervention: Critical-sized defect
Number of subjects: 37
Study 22714001 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg daclatasvir
Number of subjects: 48
Study 22714001 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg daclatasvir
Number of subjects: 48
Study 22714001 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg daclatasvir
Number of subjects: 48
Study 22714001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20500832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg
Number of subjects: 156
Study 20500832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 17312304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 7145
Study 17312304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7145
Study 17312304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (during active treatment)
Number of subjects: 7145
Study 17312304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (after treatment)
Number of subjects: 7145
Study 17312304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 7145
Study 12716266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 183
Study 12716266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 183
Study 12716266 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Fluoxetine or Nortriptyline)
Number of subjects: 183
Study 11134880 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiroflex C10 IOL
Number of subjects: 107
Study 11134880 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiroflex C11 IOL
Number of subjects: 107
Study 9552825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifluorid 12 (CaF2 6% and NaF 6%)
Number of subjects: 25
Study 9552825 — intervention group
Group type: COMPARATOR
Intervention: Control (NaF 6%)
Number of subjects: 25
Study 9552825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bifluorid 12 and Control)
Number of subjects: 25
Study 1588150 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMP (Hib capsular polysaccharide linked to the outer membrane protein complex of Neisseria meningitidis)
Number of subjects: 2
Study 1588150 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC (Hib oligosaccharide covalently linked to the nontoxic mutant diphtheria toxin CRM197)
Number of subjects: 2
Study 1588150 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconjugated Hib capsular polysaccharide
Number of subjects: 2
Study 3898780 — intervention group
Group type: EXPERIMENTAL
Intervention: Benexol B12
Number of subjects: 40
Study 3898780 — intervention group
Group type: COMPARATOR
Intervention: Cronassial
Number of subjects: 40
Study 28711384 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT)
Number of subjects: 158
Study 28711384 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy (RT) alone
Number of subjects: 158
Study 27110603 — intervention group
Group type: EXPERIMENTAL
Intervention: Papilla preservation crown-lengthening procedure (PPCL)
Number of subjects: 30
Study 27110603 — intervention group
Group type: COMPARATOR
Intervention: Apically positioned flap with buccal approach (APF-B)
Number of subjects: 30
Study 27110603 — intervention group
Group type: COMPARATOR
Intervention: Apically positioned flap with buccal and palatal approach (APF-BP)
Number of subjects: 30
Study 24595864 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Monitoring (HM)
Number of subjects: 3521
Study 24595864 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring (IPE)
Number of subjects: 3521
Study 22037349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5202
Study 22037349 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (≥7.5% body weight)
Number of subjects: 5202
Study 22037349 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (mean +4.0±6.1 kg) with pioglitazone
Number of subjects: 5202
Study 22037349 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 5202
Study 21031576 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapy with a mixture of 3 myelin peptides: MBP85-99, PLP139-151, and MOG35-55
Number of subjects: 30
Study 21031576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19007923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for perfectionism
Number of subjects: 48
Study 19007923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for BN
Number of subjects: 48
Study 19007923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15994746 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized GH treatment
Number of subjects: 59
Study 15994746 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose GH treatment
Number of subjects: 59
Study 11986111 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wavelength automated perimetry (SWAP)
Number of subjects: 152
Study 11986111 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency doubling technology perimetry (FDT)
Number of subjects: 152
Study 11986111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern electroretinography (PERG)
Number of subjects: 152
Study 11986111 — intervention group
Group type: EXPERIMENTAL
Intervention: Test battery of SWAP and PERG P1N2-amplitude
Number of subjects: 152
Study 11986111 — intervention group
Group type: COMPARATOR
Intervention: SWAP and FDT
Number of subjects: 152
Study 10703945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients (CD123+ and CD11c+ cells)
Number of subjects: 40
Study 10703945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer patients with distant organ metastases (CD123+ and CD11c+ cells)
Number of subjects: 40
Study 10703945 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 40
Study 8699994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ATP at 50 micrograms/kg/minute
Number of subjects: 14
Study 8699994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ATP at 75 micrograms/kg/minute
Number of subjects: 14
Study 8699994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ATP at 100 micrograms/kg/minute
Number of subjects: 14
Study 8699994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ATP (all doses)
Number of subjects: 14
Study 1928853 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 and hydrocortisone (100 mg hydrocortisone intravenously, 2 or 4 micrograms T3 every hour or half hour)
Number of subjects: 40
Study 1928853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study 6281143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 6281143 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study 31958548 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated stimulation at short inter-trial intervals (ITIs)
Number of subjects: 56
Study 31958548 — intervention group
Group type: COMPARATOR
Intervention: Long inter-trial intervals (ITIs)
Number of subjects: 56
Study 31958548 — intervention group
Group type: EXPERIMENTAL
Intervention: First acceleration-deceleration of HR
Number of subjects: 56
Study 31958548 — intervention group
Group type: EXPERIMENTAL
Intervention: Second acceleration-deceleration of HR
Number of subjects: 56
Study 30743314 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxelotor 900 mg for 15 days
Number of subjects: 48
Study 30743314 — intervention group
Group type: COMPARATOR
Intervention: Voxelotor (various doses: 100, 400, 1000, 2000, or 2800 mg) single dose
Number of subjects: 48
Study 30743314 — intervention group
Group type: COMPARATOR
Intervention: Voxelotor (300, 600, or 900 mg) multiple doses for 15 days
Number of subjects: 48
Study 30743314 — intervention group
Group type: COMPARATOR
Intervention: Voxelotor in SCD patients (1000 mg)
Number of subjects: 48
Study 30743314 — intervention group
Group type: COMPARATOR
Intervention: Voxelotor (various doses)
Number of subjects: 48
Study 27932413 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of coronary artery disease (CAD), NT-proBNP, GDF-15
Number of subjects: 5174
Study 27932413 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 5174
Study 27932413 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 5174
Study 27932413 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT-hs
Number of subjects: 5174
Study 27932413 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP or GDF-15
Number of subjects: 5174
Study 26551372 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized local anesthesia (Wand)
Number of subjects: 100
Study 26551372 — intervention group
Group type: COMPARATOR
Intervention: Traditional local anesthesia (syringe)
Number of subjects: 100
Study 24171870 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg Scale
Number of subjects: 73
Study 24171870 — intervention group
Group type: EXPERIMENTAL
Intervention: NRS + FACES
Number of subjects: 73
Study 24171870 — intervention group
Group type: EXPERIMENTAL
Intervention: Likert Scale
Number of subjects: 73
Study 24171870 — intervention group
Group type: COMPARATOR
Intervention: Borg Scale vs NRS + FACES
Number of subjects: 73
Study 24171870 — intervention group
Group type: COMPARATOR
Intervention: Subjective ratings vs heart rate
Number of subjects: 73